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monitoring performed for safety and efficacy monitoring during the past 12 months of
simvastatin therapy. Among these, no significant abnormal CK or liver enzyme values
were observed. Conclusions: The drug selections of many healthcare providers who use
simvastatin are now in conflict with the changed safety labeling of this agent. Heightened
by insufficient safety monitoring, this change represents an important shift in legal liability
from industry to the provider community.
11:45 a.m.
882-6 Delay in Dose Titration of Lipid-Lowering Therapy 
Leads to Adverse Cardiovascular Outcomes
Amy S. Friend, Masoor Kamalesh, Ellen M. Schellhase, Tamara S. Evans, Indiana 
University Medical Center and VAMC, Indianapolis, IN
Background: Despite a plethora of data showing benefits of lipid lowering, a majority of
the patients are not at their target lipid levels. We investigated titration frequency, time to
achievement of target lipid levels, and clinical course of patients during dose titration in a
large teaching hospital.
Methods: A retrospective chart review was conducted at this institution by reviewing a
random sample of 100 patient charts receiving simvastatin 80 mg. Documented cardio-
vasular events while on statin therapy and timeframe for statin titration and number of
titrations to maximal statin dose were collected.
Results: Patients were 96% male with mean age 65.3 years (range 44-86). Of these
79% were white. Target low density lipoprotein cholesterol (LDL) level was <100mg/dL for
84% of the group. LDL target level was achieved in 70% of the patients reviewed. The
number of titrations to achieve a dose of simvastatin 80 mg ranged from 1 to 6 and
occurred over a time period ranging from 3 months to 6.8 years. The average titration
period was 2.25 years for the overall population. Average LDL reduction from baseline
was 32% (p=0.0001) and high density lipoprotein increased 4.7% (p=0.001). There were
25 cardiovascular events in 17 patients during the titration period. These included 13
anginal episodes requiring hospitalization, 10 revascularizations, and 2 myocardial infarc-
tions. Of these 17 patients, 16 eventually achieved their target LDL level. Average titration
period in this group was 3.0 years compared with 2.1 years for those who did not have an
event but achieved their target LDL level (p=0.14). Conclusions: In clinical practice,
there is an excessive delay in titrating lipid-lowering drugs to optimal dose. This exposes
patients to a high risk of atherosclerosis related events. Dosage adjustments of statins
can be made at intervals of 4 weeks. Thus patients could theoretically be at their optimal
dose within 8 - 12 weeks of initiation of lipid-lowering therapy. Clinicians need to be more
adherent to published titration guidelines so that patients achieve their desired LDL goal
in a more expedient timeframe in order to potentially reduce negative cardiovascular out-
comes.
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888-1 N-Terminal Pro Brain Natriuretic Peptide Predicts 
Cardiovascular Events in Patients With Hypertension 
and Left Ventricular Hypertrophy: A LIFE Study
Michael H. Olsen, Kristian Wachtell, Christian Hall, Hans Ibsen, Jens Rokkedal, Sverre 
E. Kjeldsen, Richard B. Devereux, Björn Dahlöf, Per Hildebrandt, Glostrup University 
Hospital, Copenhagen, Denmark, Frederiksberg University Hospital, Copenhagen, 
Denmark
Background: We have previously suggested that N-terminal pro brain natriuretic peptide
(Nt-proBNP) is a cardiovascular risk factor in hypertension. We wanted to test this
hypothesis in a new larger group of patients with hypertension and electrocardiographic
left ventricular (LV) hypertrophy.
Methods: In 945 hypertensive patients from the LIFE study, we measured traditional car-
diovascular (CV) risk factors, urine albumin/creatinine ratio (UACR) and Nt-proBNP by
immunoassay after two weeks of placebo treatment. The patients were followed for
55±0.6 months recording the composite endpoint (CEP) of CV death, non-fatal stroke or
non-fatal myocardial infarction.
Results: Nt-proBNP above the median value of 20.1 pmol/l was associated with more
CV events (Table 1). In Cox regression analyses log(Nt-proBNP) (hazard ratio (HR)=2.40
per 10-fold increase**) predicted CEP independently of total serum cholesterol (HR=1.37
per mmol/l**), serum high density lipoproteins (HR=0.50 per mmol/l*) and logUACR
(HR=1.86**). CV death was predicted by log(Nt-proBNP) (HR=3.07 per 10-fold
increase**) independently of total serum cholesterol (HR=1.69 per mmol/l***) and of
logUACR (HR=2.31**). Framingham Risk Score and LV mass assessed by electrocardio-
graphy did not enter the model. *P<0.05, **P<0.01, ***P<0.001
Conclusion: Nt-proBNP is a strong CV risk factor superior to traditional risk factors in
hypertensive patients with LV hypertrophy and especially in patients without history of CV
disease or diabetes.
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888-2 Does Left Ventricular Hypertrophy Predict Sudden 
Cardiac Death Independent of Ischemia? The LIFE 
Study
Kristian Wachtell, Michael H. Olsen, Richard B. Devereux, Hans Ibsen, Sverre E. 
Kjeldsen, Stevo Julius, Lars H. Lindholm, Markku S. Nieminen, Björn Dahlöf, Glostrup 
University Hospital, Glostrup, Denmark, The Weill Medical College of Cornell University, 
New York, NY
Background: Patients with left ventricular hypertrophy (LVH) have been shown to have
increased incidence of sudden cardiac death (SCD). This analysis assessed predictors
of SCD in a large cohort of hypertensive patients with ECG LVH.
Methods: In the LIFE (n=9,193), a double-blind, randomized, parallel-group trial, 190
patients died suddenly within 24 hours of onset of symptoms during the average 4.8 year
follow-up period.
Results: Patients with SCD were older, more often male and had higher ECG LVH, albu-
minuria and more frequent history of atrial fibrillation, diabetes, coronary heart and cere-
bral vascular disease. SCD was not predicted by systolic or diastolic blood pressure,
body mass index, cholesterol, potassium or history of peripheral vascular disease. In
multivariate Cox analysis Cornell voltage-duration product predicted SCD (Table) and
remained predictive in a subgroup (n=3,617) without history of coronary heart disease or
albuminuria. The 1-year Cornell voltage-duration product was more predictive than base-
line indicating that regression of LVH is more predictive than baseline LVH. Treatment
with losartan compared to atenolol was not associated with a lower SCD rate (HR=0.88
[95% CI: 0.66-1.17], p=0.364).
Conclusion: Baseline LVH predicts SCD independent of history of coronary heart dis-
ease and other cardiovascular risk factors and remains predictive in the subpopulation
without signs of atherosclerosis. Furthermore, losartan vs. atenolol treatment appears to
benefit SCD equally.
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888-3 Racial Differences in the Prognostic Value of the 
Electrocardiographic Strain Pattern in Hypertensive 
Patients: The LIFE Study
Peter M. Okin, Richard B. Devereux, Markku S. Nieminen, Jackson T. Wright, Sverker 
Jern, Anne L. Taylor, Robert A. Phillips, Vasilios Papademetriou, Luther T. Clark, 
Elizabeth O. Ofili, Otelio S. Randall, Lasse Oikarinen, Matti Viitasalo, Lauri Toivonen, 
Björn Dahlöf, The LIFE Study Investigators, Weill Medical College of Cornell University, 
New York, NY
Background: The ECG strain pattern of downsloping convex ST segment with inverted
asymmetrical T-wave in leads V5 or V6 is associated with increased risk of cardiovascu-
lar (CV) morbidity and mortality in the overall LIFE study population. African Americans
(AA) have higher rates of ECG strain, CV and all-cause mortality in LIFE, but whether
ECG strain is associated with increased risk in AA is unclear.
Methods: Baseline ECGs were examined in 8,854 hypertensive patients (515 [5.8%] AA)
enrolled in LIFE. All patients were treated in a blinded manner with atenolol- or losartan-
based regimens and followed for a mean of 4.7±1.1 years.
Results: AA patients had a higher prevalence of ECG strain (27.8 vs 9.9%, p<.001), were
younger, more likely to be male, current smokers, diabetic, have a history of ischemic
heart disease, stroke or congestive heart failure, had higher Sokolow-Lyon voltage but
lower Cornell products and greater albuminuria. In non-AA patients, strain was associ-
ated with higher 5-year event rates of CV mortality, myocardial infarction (MI), stroke, all-
cause mortality, and the LIFE composite endpoint of CV mortality, MI or stroke (Table). In
contrast, AA patients with and without strain had similar rates of all endpoints except MI.
These findings persisted after controlling for baseline differences and treatment effect in
Table 1
No CV disease 
or diabetes
No CV disease 
or diabetes
CV disease or 
diabetes
CV disease or 
diabetes
Nt-proBNP Low High Low High
CEP (%) 3.2*** 11.0 6.5* 17.3
CV death (%) 0.5*** 5.0 3.3* 10.9
Stroke (%) 1.1** 5.0 2.2* 9.6
Cox regression analysis Hazard Ratio 95% CI P
Age (year) 1.04 1.01-1.06 =0.007
Cornell voltage duration product (100 mV*msec) 1.02 1.01-1.03 =0.001
Framingham risk score (%) 1.04 1.03-1.06 <0.001
Urine albumin/creatinine (mg/mmol) 1.40 1.12-1.74 =0.003
History of coronary heart disease 2.03 1.43-2.88 <0.001
History of cerebro vascular disease 1.50 0.96-2.35 =0.077
Heart rate (10 bpm) 1.29 1.14-1.46 <0.001
History of atrial fibrillation 2.11 1.30-3.40 =0.002
